Prof. Fischer

Prof. Dr. med. Thomas Fischer
Zentrum für Innere Medizin (ZIM): Universitätsklinik für Hämatologie und Onkologie (KHAE)
Aktuelle Projekte
- Neue Wirkstoffe auf pflanzlicher Basis für ältere Menschen mit chronischen Bluterkrankungen
Laufzeit: 01.07.2019 - 31.12.2021 - Dysregulation of integrin function and induction of inflammation in JAK2-mutated myeloproliferative neoplasia.
Laufzeit: 01.01.2014 - 31.12.2021 - ABINEP M3-project 1: Influence of the intestinal microbiome on infections, course disease and success of treatment on cytostatic drug-treated hemic-oncological patients
Laufzeit: 01.01.2017 - 30.06.2021
Abgeschlossene Projekte
- TeleBlut - Individualisierte Anämie- und Polyzythämie- Früherkennung
Laufzeit: 01.04.2016 - 31.03.2019 - Identifizierung neuer Zielmoleküle für die klinische Therapie der akuten myeloischen Leukämie (AML)
Laufzeit: 01.07.2014 - 30.06.2017 - Understanding misbalanced signalling by JAK2-V617F in myloproliferative neoplasms fusing qualitative and quantitative modelling
Laufzeit: 01.01.2013 - 31.12.2015 - Aberrante Aktivierung der Signaltransduktion durch differentielle Protein-Protein-Interaktion von mutierten FLT3-Rezeptoren
Laufzeit: 01.03.2010 - 31.12.2014 - Identifizierung und funktionelle Charakterisierung von onkogenen Kinase-Signalkaskaden bei der FLT3-ITD-positiven akuten myeloischen Leukämie (AML).
Laufzeit: 01.10.2009 - 31.12.2012 - Moguntinone als neue Therapieoption bei Malignomen
Laufzeit: 01.05.2009 - 30.04.2012 - Differentielle Signaltransduktion von FLT3- Rezeptoren mit atypischen, non- juxtamembranären ITD-Mutationen
Laufzeit: 01.07.2008 - 30.06.2011 - Funktionelle Charakterisierung von onkogenen Signaltransduktionswegen in Weichgewebssarkomen
Laufzeit: 01.07.2008 - 30.06.2011 - Vergleichende Kinomanalyse in CD34-positiven hämatopoetischen Zellen von Patienten mit JAK2V617F-positiven myeloproliferativen Erkrankungen
Laufzeit: 01.10.2007 - 30.09.2009 - Untersuchungen zur primären Resistenz von leukämischen Blasten der akuten myeloischen Leukämie (AML) auf FLT3-Tyrosinkinase-Inhibitoren (FLT3-TKI)
Laufzeit: 01.01.2006 - 30.06.2009
2019
Abstrakt
Infectiousn complications in patients with multiple myeloma, malignant lymphoma and germ cell tumor receiving autologous blood stem cell transplantation - a retrospective single center analysis
In: Bone marrow transplantation - London: Springer Nature, Bd. 54.2019, Suppl. 1, P458, Seite 440
Begutachteter Zeitschriftenartikel
Targeting RIPK1 in AML cells carrying FLT3-ITD
In: International journal of cancer - Bognor Regis: Wiley-Liss, Bd. 145.2019, 6, S. 1558-1569
Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia
In: PLOS ONE - San Francisco, California, US: PLOS, Volume 14.2019, 7, article e0204540, insgesamt 26 Seiten
Clinical predictors and prognostic impact of recovery of wall motion abnormalities in takotsubo syndrome - results from the International Takotsubo Registry
In: Journal of the American Heart Association - New York, NY: Association, Bd. 8.2019, 21, Art.-Nr. e011194, insges. 11 S.
Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling
In: Cell communication and signaling - London: Biomed Central, Bd. 17.2019, Art.-Nr. 5, insges. 13 S.
SDF1 α-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/ AKT, PLCγ1 and RhoA. Letters to the editor
In: Haematologica - Pavia: Ferrata Storti Foundation, Bd. 104.2019, 7, S. e288-e292
Milzzyste nach Bauchtrauma?
In: Deutsches Ärzteblatt international - Köln: Dt. Ärzte-Verl., Bd. 116.2019, 20, S. 362
Primary ecthyma gangraenosum due to central venous catheter-related bloodstream infection with Pseudomonas aeruginosa
In: Infection - München: Urban & Vogel, Bd. 47.2019, 2, S. 333-334
Dose reduction and high-risk disease as risk factors for early death in primary CNS lymphoma. Letter to the editor
In: Leukemia and lymphoma - London [u.a.]: Taylor & Francis Group, Bd. 60.2019
Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? - Results from a multicentre, retrospective study
In: Annals of hematology - Berlin: Springer, Bd. 98.2019, 12, S. 2729-2737
2018
Abstrakt
Therapeutic potential of Axl blockade in BCR-ABL negative myeloproliferative neoplasms (MPN)
In: Oncology research and treatment - Basel: Karger, Bd. 41.2018, Suppl. 4, V118, Seite 27
Infectious complications in patients with multiple myeloma, malignant lymphoma and germ cell tumor receiving autologous blood stem cell transplantation - a retrospective single center analysis
In: Oncology research and treatment - Basel: Karger, Bd. 41.2018, Suppl. 4, P288, Seite 90-91
A randomized clinical trial of coping support intervention for parents of adolescent and young adults (AYA) with hematological malignancies
In: Oncology research and treatment - Basel: Karger, Bd. 41.2018, Suppl. 1, Abstract 550, Seite 25
Randomisierte klinische Studie zu einer Coping Support Intervention für Eltern von Adoleszenten und jungen Erwachsenen (AYA) mit hämatologischen Malignomen
In: Psychotherapie, Psychosomatik, medizinische Psychologie - Stuttgart [u.a.]: Thieme, Bd. 68.2018, 8, Seite e17
Risk of central venous catheter (CVC)-related bloodstream infections (CRBSI) in cancer patients (pts) with or without neutropenia at time of CVC insertion
In: Oncology research and treatment - Basel: Karger, Bd. 41.2018, Suppl. 4, V428, Seite 145
Begutachteter Zeitschriftenartikel
JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation
In: The journal of clinical investigation - Ann Arbor, Mich: ASCJ, Bd. 128.2018, 10, S. 4359-4371
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors
In: Blood - Washington, DC: American Society of Hematology, Bd. 132.2018, 1, S. 67-77
Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation
In: Annals of hematology - Berlin: Springer, Bd. 97.2018, 5, S. 773-780
Bruton's tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia
In: Leukemia - London: Springer Nature, Bd. 32.2018, 3, S. 846-849
Mathematical modeling of RBC count dynamics after blood loss
In: Processes - Basel: MDPI, Vol. 6.2018, 9, Art. 157, insgesamt 29 S.
Nicht begutachteter Zeitschriftenartikel
Das internistische Jahr 2017 - die wichtigsten Fortschritte und Entwicklungen
In: Ärzteblatt Sachsen-Anhalt - offizielles Mitteilungsblatt der Ärztekammer Sachsen-Anhalt: offizielles Mitteilungsblatt der Ärztekammer Sachsen-Anhalt - Magdeburg: Ärztekammer Sachsen-Anhalt, Bd. 29.2018, 4, S. 17-20
2017
Abstrakt
Variant allele frequency kinetics of tyrosine kinase gene mutations in core-binding factor acute myeoloid leukemia (CBF-AML) under treatment with and without dasatinib
In: Haematologica: journal of the European Hematology Association - Pavia: Ferrata-Storti Foundation, Bd. 102.2017, Suppl. 2, P535, S. 204-205
CTLA-4 mediated effects on STATs regulate differentiation and plasticity of Tc17 cells
In: European journal of immunology- Weinheim: Wiley VCH, 1971, Bd. 47.2017, Suppl. 2, P395, S. 277
Preclinical evaluation of immuno-/proteasome inhibitors in soft-tissue sarcoma
In: Oncology research and treatment - Basel: Karger, Bd. 40.2017, Suppl. 3, V415, S. 111-112
Three cases of herpes virus reactivation after allogeneic stem cell transplantation
In: Bone marrow transplantation - London: Springer Nature, Bd. 52.2017, Suppl. 1, S. S268
Epidemiological, genetic and clinical characterization of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) (NCT01252485)
In: Oncology research and treatment - Basel: Karger, Bd. 40.2017, Suppl. 3, P198, S. 45-46
NFKB pathway promotes tumor progression through Brutons tyrosine kinase in MLL+ acute myeloid leukemia
In: Haematologica: journal of the European Hematology Association - Pavia: Ferrata-Storti Foundation, Bd. 102.2017, Suppl. 2, E865, S. 356-357
A simple prognostic index for prediction of central venous catheter-related bloodstream infections in patients with haematological malignancies (CIPS-H)
In: Oncology research and treatment - Basel: Karger, Bd. 40.2017, Suppl. 3, V765, S. 222
Impact of treatment delay on prognosis in patients with primary CNS lymphoma
In: Oncology research and treatment - Basel: Karger, Bd. 40.2017, Suppl. 3, P282, S. 77
Early death in patients with primary CNS lymphoma
In: Oncology research and treatment - Basel: Karger, Bd. 40.2017, Suppl. 3, P281, S. 76
Begutachteter Zeitschriftenartikel
The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs
In: OncoImmunology- Abingdon: Taylor & Franics, 2012, Bd. 6.2017, 2, Art.-Nr. e1273300, insges. 5 S.
The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells
In: Cellular signalling - Amsterdam [u.a.]: Elsevier Science, Bd. 35.2017, S. 37-47
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma - DSMM XI trial
In: British journal of haematology: the official journal of the British Society for Haematology and the European Haematology Association - Oxford [u.a.]: Wiley-Blackwell, Bd. 179.2017, 4, S. 586-597
Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma
In: Leukemia: normal and malignant hemopoiesis : a peer-reviewed journal - London: Springer Nature, Bd. 31.2017, 6, S. 1463-1466
RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts
In: Cell death and differentiation- Houndmills, Basingstoke: Nature Publishing Group, 1997, Bd. 24.2017, 2, S. 371-383
JAK2-V617F activates β1-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1
In: Leukemia: normal and malignant hemopoiesis : a peer-reviewed journal - London: Springer Nature, Bd. 31.2017, 5, S. 1223-1226
Gain of function in Jak2V617F positive T-cells. Letter to the editor
In: Leukemia: normal and malignant hemopoiesis : a peer-reviewed journal - London: Springer Nature, Bd. 31.2017, 4, S. 1000-1003
Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells
In: Nature Communications - [London]: Nature Publishing Group UK, Bd. 8.2017, Artikel-Nummer 311, 16 Seiten
Determination of a cutoff time point for prophylactic exchange of central venous catheters for prevention of central venous catheterrelated bloodstream infections in patients with hematological malignancies
In: Infection control and hospital epidemiology: the official journal of the Society for Healthcare Epidemiology of America - Cambridge: Cambridge Univ. Press, Bd. 38.2017, 7, S. 888-889
Impact of lymphopenia on prognosis of patients with primary central nervous system lymphoma - Letter to the editor
In: European journal of cancer - Amsterdam [u.a.]: Elsevier, Bd. 75.2017, S. 280-283
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia - letter to the editor
In: Leukemia: normal and malignant hemopoiesis : a peer-reviewed journal - London: Springer Nature, Bd. 31.2017, 5, S. 1217-1220
Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN
In: Journal of cancer research and clinical oncology: official organ of the Deutsche Krebsgesellschaft - Berlin: Springer, Bd. 143.2017, 5, S. 807-820
Diagnostic and therapeutic challenges in extragonadal yolk sac tumor with hepatoid differentiation - a case report
In: Molecular and clinical oncology: an international journal devoted to oncology - Athens: Spandidos Publ, Bd. 6.2017, 1, S. 79-82
Buchbeitrag
Tumor-Lyse-Syndrom
In: Gastroenterologie für Intensivmediziner: 68 Abbildungen - Stuttgart: Georg Thieme Verlag, S. 196-199, 2017
2016
Abstrakt
Research and science
In: Oncology research and treatment. - Basel : Karger; Bd. 39.2016, Suppl. 3, Seite 326
Effectiveness of tigecycline (TGC) in hematological patients (pts) with persisting or recurring fever - a retrospective, monocentric review of 78 cases
In: Oncology research and treatment. - Basel : Karger; Bd. 39.2016, Suppl. 3, Abs. P957, Seite 296
Characteristics and treatment of sarcoma patients in a single-center analysis
In: Oncology research and treatment. - Basel : Karger; Bd. 39.2016, Suppl. 3, Abs. P917, Seite 279-280
Expression level of JAK2-V617F determines sensitivity to tyrosine kinase inhibitor Ruxolitinib in HEK293 Flp-In cells and can be augmented by treatment with inhibitors of PI3K/Akt pathway in JAK2-V617F - positive murine progenitor cells
In: Oncology research and treatment - Basel: Karger, Bd. 39.2016, Suppl. 3, Abs. P510, Seite 148-149
LPS stimulation induces ROS formation, apoptosis, DNA damage and oxidation of cysteine residues in FLT3-ITD positive cell lines resulting in FLT3-tyrosine kinase inhibitor resistance
In: Haematologica : journal of the European Hematology Association. - Pavia : Ferrata-Storti Foundation; Bd. 101.2016, s1, Abs. E877, S. 360
Reactive oxygen species (ROS) modulates sensitivity to FLT3-tyrosine kinase inhibitors in murine and human FLT3-ITD positive AML cell lines
In: Haematologica : journal of the European Hematology Association. - Pavia : Ferrata-Storti Foundation; Bd. 101.2016, s1, Abs. E885, S. 362-363
Regulatory role of intracellular ROS levels and effects of antioxidants (NAC, Tempol) on proliferation, cell cycle and sensitivity to treatment with tyrosine kinase inhibitor Ruxolitinib in JAK2-V617F - positive myeloproliferative neoplasms
In: Oncology research and treatment. - Basel : Karger; Bd. 39.2016, Suppl. 3, Abs. P509, Seite 148
Hematopoietic Stem Cell Transplantation (HSCT) as compared to Consolidation Chemotherapy (CT) increases leukemia free survival in patients between 60 and 75 years with Acute Myelogenous Leukemia (AML) irrespective of the genetic risk - report from the AML 2004 of the East German Study Group (OSHO)
In: Oncology research and treatment - Basel: Karger, Bd. 39.2016, Suppl. 3, V29, S. 2-4
Prophylactic exchange of central venous catheters (CVC) for prevention of CVC-related bloodstream infections (CRBSI) in patients with haematological malignancies - indirect evidence from pooled data of the SECRECY registry and the COAT study
In: Oncology research and treatment - Basel: Karger, Bd. 39.2016, Suppl. 3, Abs. V44, Seite 8
Cell intrinsic induction of IP-10 in MPN
In: Oncology research and treatment. - Basel : Karger; Bd. 39.2016, Suppl. 3, Abs. V107, Seite 26
Randomized comparison of pegylated IFN-a2b versus IFN-a2b maintenance following tandem autologous transplant in multiple myeloma
In: Oncology research and treatment. - Basel : Karger; Bd. 39.2016, Suppl. 3, Abs. P546, Seite 163
Artikel in Zeitschrift
Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia - a study of the East German Haematology and Oncology Study Group (OSHO)
In: Journal of cancer research and clinical oncology: official organ of the Deutsche Krebsgesellschaft - Berlin: Springer, Bd. 142.2016, 1, S. 305-315
Begutachteter Zeitschriftenartikel
Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo
In: Leukemia: normal and malignant hemopoiesis : a peer-reviewed journal - London: Springer Nature, Bd. 30.2016, 5, S. 1220-1225
Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo
In: Haematologica: journal of the European Hematology Association - Pavia: Ferrata Storti Foundation, Bd. 101.2016, 3, S. e81-e85
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger) - a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
In: The lancet <London> - London [u.a.]: Elsevier, Bd. 388.2016, 10044, S. 565-575
Leukemogenic potency of the novel FLT3-N676K mutant
In: Annals of hematology : organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie. - Berlin : Springer, Bd. 95.2016, 5, S. 783-791
NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD positive AML cells
In: Leukemia : normal and malignant hemopoiesis ; a peer-reviewed journal. - Basingstoke : Nature Publ. Group, Bd. 30.2016, 2, S. 473-483
Optimum experimental design for patient specific mathematical leukopenia models
In: IFAC-PapersOnLine - Frankfurt: Elsevier, Bd. 49.2016, 26, S. 344-349
Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias - letter to the editor
In: Leukemia: normal and malignant hemopoiesis : a peer-reviewed journal - London: Springer Nature, Bd. 30.2016, 10, S. 2090-2093
Kinomics screening identifies aberrant phosphorylation of CDC25C in FLT3-ITD-positive AML
In: Anticancer research : international journal of cancer research and treatment. - Attiki, Bd. 36.2016, 12, S. 6249-6258
Parameter estimation for leukocyte dynamics after chemotherapy
In: IFAC-PapersOnLine - Frankfurt: Elsevier, Bd. 49.2016, 26, S. 44-49
Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma - an analysis of the German Hodgkin-Study Group
In: Leukemia and lymphoma. - London [u.a.] : Taylor & Francis Group, Bd. 57.2016, 5, S. 1067-1073
Biased low incidence of central venous catheter-related bloodstream infections in controlled clinical trials? - letter to the editor
In: Infection control and hospital epidemiology: the official journal of the Society for Healthcare Epidemiology of America - Cambridge: Cambridge Univ. Press, Bd. 37.2016, 5, S. 617-619
Hemophagocytic lymphohistiocytosis as an unusual cause of prolonged bicytopenia after chemotherapy
In: Clinical Case Reports - Chichester: Wiley, Bd. 4.2016, 10, S. 1017-1018
Characteristics and outcome of patients with primary CNS lymphoma in a real-life setting compared to a clinical trial
In: Annals of hematology : organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie. - Berlin : Springer, Bd. 95.2016, 5, S. 793-799
Buchbeitrag
Verminderung der magnetischen Nahfeldeinkopplung auf Leiterplattenebene durch reziproke Systemanalysen
In: EMV 2016: Internationale Fachmesse und Kongress für Elektromagnetische Verträglichkeit : Düsseldorf, 23. - 25.02.2016 - Aachen: Apprimus Verlag, S. 669-676 ; [Kongress: EMV 2016, Internationale Fachmesse und Kongress für Elektromagnetische Verträglichkeit, Düsseldorf, 23. - 25.02.2016]
Nicht begutachteter Zeitschriftenartikel
Das internistische Jahr 2015 - die wichtigsten Fortschritte und Entwicklungen
In: Ärzteblatt Sachsen-Anhalt: offizielles Mitteilungsblatt der Ärztekammer Sachsen-Anhalt - Magdeburg: Ärztekammer Sachsen-Anhalt, Bd. 27.2016, 5, S. 19-22
2015
Abstrakt
Requirement for phospholipase C gamma 1 (PLCG1) in development and maintenance of hematopoietic stem- and progenitor cells
In: Haematologica : journal of the European Hematology Association. - Pavia : Ferrata-Storti Foundation; Bd. 100.2015, Suppl. 1, Abs. E1133, S. 452
Results from two phase 3 studies of post-transplant bortezomib (BTZ) consolidation vs observation (OBS) in patients with newly diagnosed multiple myeloma (NDMM)
In: Haematologica : journal of the European Hematology Association. - Pavia : Ferrata-Storti Foundation; Bd. 100.2015, Suppl. 1, Abs. S426, S. 151
The novel FLT3-N676K mutant induces acute leukemia independently of the Inv(16) chimeric gene CBFB-MYH11
In: Blood : journal of the American Society of Hematology. - Stanford, Calif : HighWire Press, Bd. 126.2015, 23, S. 1383
Psycho-oncologic interventions for parents of cancer patients - systematic review
In: Oncology research and treatment. - Basel : Karger; Bd. 38.2015, Suppl. 5, V565, S. 172
The somatic burden score - a quantitative tool to evaluate the somatic burden due to chemotherapy-induced adverse events
In: Oncology research and treatment. - Basel : Karger; Bd. 38.2015, Suppl. 5, V630, S. 192
Distinct and non-overlapping functions of LLGL1 and scribble in hematopoietic stem cells
In: Experimental hematology: journal for hematology, stem cell biology and transplantation : official publication of the ISEH - International Society for Experimental Hematology - Kidlington [u.a]: Elsevier, Bd. 43.2015, 9 Suppl., Abs. 3065, S. S67
Delayed entry of blood cultures into blood culture incubators has no negative effect of on overall culture positivity
In: Oncology research and treatment. - Basel : Karger; Bd. 38.2015, Suppl. 5, V628, S. 191-192
Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM)
In: Journal of clinical oncology / Englische Ausgabe - Alexandria, Va: American Society of Clinical Oncology, Bd. 33.2015, 15 Suppl., Abs. 8511, insges. 1 S.
A pro-active follow-up with higher completeness can significantly influence survival data
In: Oncology research and treatment. - Basel : Karger; Bd. 38.2015, Suppl. 5, P508, S. 155
Clinical outcome of primary CNS lymphoma comparing the setting of real-life with a clinical trial - a single centre experience of 95 patients
In: Oncology research and treatment. - Basel : Karger; Bd. 38.2015, Suppl. 5, V707, S. 211-212
Begutachteter Zeitschriftenartikel
Evolutionarily conserved signaling pathways - Acting in the shadows of acute myelogenous leukemia's genetic diversity
In: Clinical cancer research - Philadelphia, Pa. [u.a.]: AACR, Bd. 21.2014, 2, S. 240-248, 2015
Sustained remission of blastic plasmacytoid dendritic cell neoplasm after unrelated allogeneic stem cell transplantation - a single center experience
In: Annals of hematology: organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie - Berlin: Springer, Bd. 94.2015, 2, S. 283-287
How health-related quality-of-life outcomes in patients with acute promyelocytic leukemia can help physicians in decision making. Correspondence
In: Journal of clinical oncology: JCO : official journal of the American Society of Clinical Oncology - Alexandria, Va: American Society of Clinical Oncology, Bd. 33.2015, 9, S. 1090-1091
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
In: Neurology: official journal of the American Academy of Neurology - Philadelphia, Pa: Wolters Kluwer, Bd. 84.2015, 12, S. 1242-1248
Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke
In: Acta neuropathologica - Berlin: Springer, Bd. 129.2015, 2, S. 259-277
Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function
In: Leukemia : normal and malignant hemopoiesis ; a peer-reviewed journal. - Basingstoke : Nature Publ. Group, Bd. 30.2016, 4, S. 991-995
Central venous catheter-related bloodstream infections in obese hematologic patients. Letter to the editor
In: Infection control and hospital epidemiology: the official journal of the Society for Healthcare Epidemiology of America - Cambridge: Cambridge Univ. Press, Bd. 36.2015, 8, S. 995-996
Prediction of central venous catheterrelated bloodstream infections (CRBSIs) in patients with haematologic malignancies using a modified Infection Probability Score (mIPS)
In: Annals of hematology: organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie - Berlin: Springer, Bd. 94.2015, 9, S. 1451-1456
Weichteiltumoren - allgemein-klinische Aspekte ; chirurgische und medikamentöse Therapie
In: Der Onkologe : Organ der Deutschen Krebsgesellschaft e.V. - Berlin : Springer, Bd. 21.2015, 12, S. 1147-1161
Epo-induced erythroid maturation is dependent on Plc[gamma]1 signaling
In: Cell death and differentiation - Houndmills, Basingstoke: Nature Publishing Group, Bd. 22.2015, 6, S. 974-985
Buchbeitrag
Efficient analysis and reduction of magnetic near-field-coupling in mixed-signal PCBs via the reciprocity principle
In: Proceedings of IEEE International Symposium on Electromagnetic Compatibility and EMC Europe - Piscataway, NJ: IEEE, S. 91-95, 2015
Nicht begutachteter Zeitschriftenartikel
Eine Ärztin mit großem Einsatz und bei Patienten und MItarbeitern gleichermaßen beliebt - Im Gedenken an Prof. Dr. med. Astrid Franke
In: UMMD aktuell: Informationen für Patienten, Mitarbeiter und Studierende des Universitätsklinikums Magdeburg A.ö.R. und der Medizinischen Fakultät der Otto-von-Guericke-Universität Magdeburg - Magdeburg: Klinikumsvorstand, 1, S. 15, 2015
2014
Abstrakt
Distinct biological and transcriptional features of FLT3-ITD variants in vitro and in vivo
In: Oncology research and treatment - Basel: Karger, Bd. 37.2014, Suppl. 5, V641, S. 206
Epidemiological analysis of multidrug-resistant Gramnegative bacteria (MRGN) among haemato-oncological patients
In: Oncology research and treatment - Basel: Karger, Bd. 37.2014, Suppl. 5, P874, S. 292
G-PCNSL-SG-1 randomised phase III trial of high-dose methotrexate with or without whole-brain radiotherapy for primary central nervous system lymphoma (PCNSL) - long-term follow-up
In: Oncology research and treatment - Basel: Karger, Bd. 37.2014, Suppl. 5, V122, S. 33
Impact of cold shock protein Ybx1 on hematopoietic stem cell development and function
In: Haematologica: journal of the European Hematology Association - Pavia: Ferrata-Storti Foundation, Bd. 99.2014, Suppl.1, S. 175-176
Rapid induction of cytological remission by bendamustine in a rare case of T-PLL with leukostasis symptoms
In: Oncology research and treatment - Basel: Karger, Bd. 37.2014, Suppl. 5, P787, S. 258
Overexpression of the Cell Division Cycle 25C phosphatase in a two-hit-model of acute myeloid leukemia (AML) suppresses apoptosis upon cytotoxic treatment
In: Oncology research and treatment - Basel: Karger, Bd. 37.2014, Suppl. 5, P417, S. 125
Mathematical modelling of neutropenia of AML patients treated with chemotherapy
In: Oncology research and treatment - Basel: Karger, Bd. 37.2014, Suppl. 5, P501, S. 159
Prediction of central venous catheter- (CVC-) related bloodstream infections (CRBSIs) in cancer patients (pts) using the Infection Probability Score (IPS): first results from the SECRECY registry
In: Oncology research and treatment - Basel: Karger, Bd. 37.2014, Suppl. 5, V301, S. 94
JAK2V617F mutation is sufficient for autocrine induction of IP-10 in hematopoietic cells
In: Oncology research and treatment - Basel: Karger, Bd. 37.2014, Suppl. 5, V618, S. 199
Begutachteter Zeitschriftenartikel
DAPK-HSF1 interaction as a positive-feedback mechanism stimulating TNF-induced apoptosis in colorectal cancer cells
In: Journal of cell science: Company of Biologists - Cambridge: Company of Biologists Limited, Bd. 127.2014, 24, S. 5273-5287
Quantitative tool to evaluate the somatic burden due to chemotherapy-induced adverse events - the somatic burden score
In: Supportive care in cancer. - Berlin : Springer, Bd. 22.2014, 11, S. 3089-3099
Allogeneic stem cell transplantation for mantle cell lymphoma - final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO)
In: Annals of hematology. - Berlin : Springer, Bd. 93.2014, 9, S. 1587-1597
Multidrug-resistant gram-negative bacteria in hematology and oncology
In: Infection control and hospital epidemiology: the official journal of the Society for Healthcare Epidemiology of America - Cambridge: Cambridge Univ. Press, Bd. 35.2014, 9, S. 1203-1204
The incidence of norovirus infections in cancer patients shows less seasonal variability compared to patients with other diseases. Letter to the editor
In: Annals of hematology. - Berlin : Springer, Bd. 93.2014, 5, S. 889-890
Clinically relevant doses of FLT3-kinase inhibitors Quizartinib and Midostaurin do not impair T-cell reactivity and function
In: Haematologica: journal of the European Hematology Association - Pavia: Ferrata Storti Foundation, Bd. 99.2014, 6, S. e90-e93
2013
Abstrakt
A case of acute myeloid leucaemia after EHEC infection
In: Onkologie. - Basel : Karger; Bd. 36.2013, Suppl. 7, P565, S. 166
Allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm
In: Bone marrow transplantation. - London : Nature Publishing Group; Bd. 48.2013, Suppl.2s, R1531, S. S541
Health-related quality of life and distress in patients with systemic malignancies stratified by age: AYA patients have the worst mental health
In: Onkologie. - Basel : Karger; Bd. 36.2013, Suppl. 7, V399, S. 108-109
The Magdeburg model of care for adolescents and young adults with cancer (MC AYA): A pilot approach
In: Onkologie. - Basel : Karger; Bd. 36.2013, Suppl. 7, P552, S. 162
Successful treatment of recurrent Desmoid fibromatosis in an adult using low dose chemotherapy with methotrexate and vinblastine
In: Onkologie. - Basel : Karger; Bd. 36.2013, Suppl. 7, P819, S. 249
Epidemiological data on norovirus infections in cancer patients, 2009-2012
In: Onkologie. - Basel : Karger; Bd. 36.2013, Suppl. 7, P271, S. 82
Begutachteter Zeitschriftenartikel
A genome-wide RNAi screen identifies proteins modulating aberrant FLT3-ITD signaling
In: Leukemia. - Basingstoke : Nature Publ. Group, Bd. 27.2013, insges. 10 S.
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
In: Leukemia. - Basingstoke : Nature Publ. Group, Bd. 27.2013, 8, S. 1628-1636
The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML
In: The journal of experimental medicine. - New York, NY : Rockefeller Univ. PressThe journal of experimental medicine <New York, NY>, Bd. 210.2013, 1, S. 15-22
Identification of DAPK as a scaffold protein for the LIMK/cofilin complex in TNF-induced apoptosis
In: International journal of biochemistry & cell biology. - Amsterdam : Elsevier, Bd. 45.2013, 8, S. 1720-1729
Caught by an acute leukaemia: Facing patients' own experiences
In: Leukemia research. - Amsterdam : Elsevier, Bd. 37.2013, 5, S. 481-482
Cold shock Y-box protein-1 proteolysis autoregulates its transcriptional activities
In: Cell communication and signaling. - London : Biomed Central; Bd. 11.2013, 1, Art.-Nr. 63, insges. 16 S.
Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells. Letter to the editor
In: Leukemia. - Basingstoke : Nature Publ. Group, Bd. 27.2013, 7, S. 1567-1570
Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature
In: Journal of hematology & oncology. - London : Biomed Central, Bd. 6.2013, insges. 6 S.
Nicht begutachteter Zeitschriftenartikel
Maligne Lymphome - Diagnostik und Therapie
In: Tumorzentrum aktuell // Tumorzentrum Magdeburg/Sachsen-Anhalt. - Magdeburg : Tumorzentrum, Bd. 10.2013, 1, S. 24-28
2012
Anderes Material
Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL) - experience from the G-PCNSL-SG1 trial
In: Annals of oncology: official journal of the European Society for Medical Oncology - Oxford: Oxford Univ. Press, Bd. 23.2012, 9, S. 2374-2380
Artikel in Zeitschrift
Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression
In: Cell communication and signaling - London: Biomed Central, Bd. 10.2012, Artikel-Nr. 19, insges. 15 S.
Begutachteter Zeitschriftenartikel
Strukturierte psychoonkologische Kurzintervention für Eltern Adoleszenter und junger Erwachsener (AYA) mit malignen hämatologischen Erkrankungen: eine randomisierte klinische Studie
In: Tumorzentrum aktuell // Tumorzentrum Magdeburg/Sachsen-Anhalt. - Magdeburg : Tumorzentrum, Bd. 9.2012, 1, S. 30-35
Aktuelle und neue Therapieoptionen bei myeloproliferativen Erkrankungen
In: Tumorzentrum aktuell // Tumorzentrum Magdeburg/Sachsen-Anhalt. - Magdeburg : Tumorzentrum, Bd. 9.2012, 1, S. 21-29
Originalartikel in begutachteter internationaler Zeitschrift
High-performance liquid chromatography with ultraviolet detection and protein precipitation as a way of quantitative determination of nilotinib with and without internal standard
In: Journal of liquid chromatography & related technologies. - Philadelphia, Pa. : Taylor & Francis, Bd. 35.2012, 17, S. 2503-2510
3,4-Diarylmaleimides - a novel class of kinase inhibitors - effectively induce apoptosis in FLT3-ITD-dependent cells
In: Annals of hematology. - Berlin : Springer, Bd. 91.2012, 3, S. 331-344
Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies
In: Blood cancer journal. - London [u.a.] : Nature Publishing Group, Bd. 2.2012, 3, insges. 10 S.
Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells
In: PLoS one. - Lawrence, Kan : PLoS, Bd. 7.2012, 7, insges. 16 S.
Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
In: Leukemia. - Basingstoke : Nature Publ. Group, Bd. 26.2012, 9, S. 2061-2068
Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation
In: British journal of haematology. - Oxford [u.a.] : Wiley-Blackwell, Bd. 157.2012, 4, S. 483-492
2011
Originalartikel in begutachteter internationaler Zeitschrift
Rethinking bioactivity of FLT3 inhibitors
In: Blood. - Washington, DC : American Society of Hematology, Bd. 117.2011, 12, S. 3247-3248
Beyond diagnosis: subjective theories of illness in adult patients with acute myeloid leukemia
In: Hematology. - London [u.a.] : Maney, Bd. 16.2011, 1, S. 5-13
2010
Originalartikel in begutachteter internationaler Zeitschrift
Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3
In: Journal of clinical oncology . - Alexandria, Va. : American Society of Clinical Oncology, Bd. 28.2010, 28, S. 4339-4345
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy
In: Leukemia . - Basingstoke : Nature Publ. Group, Bd. 24.2010, 7, S. 1299-1301
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma
In: Journal of clinical oncology . - Alexandria, Va. : American Society of Clinical Oncology, Bd. 28.2010, 34, S. 5074-5080
FLT3 as a therapeutic target in AML: still challenging after all these years
In: Blood . - Washington, DC : American Society of Hematology, Bd. 116.2010, 24, S. 5089-5102
Severe paraneoplastic pemphigus in a patient with follicular lymphoma
In: European journal of haematology . - Oxford : Wiley-Blackwell, Bd. 84.2010, 4, S. 365, insges. 1 S.
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-[gamma]1-driven activation of mTOR/p70S6-kinase pathway
In: Oncogene . - Basingstoke : Nature Publ. Group, Bd. 29.2010, 5, S. 739-751
Originalartikel in begutachteter nationaler Zeitschrift
Molekularpathologie von Sarkomen: Erste Ergebnisse des Sarkomforschungsverbundes KoSar
In: Der Pathologe : Organ der Deutschen Abteilung der Internationalen Akademie für Pathologie, der Deutschen, der Österreichischen und der Schweizerischen Gesellschaft für Pathologie und des Berufsverbandes Deutscher Pathologen. - Heidelberg : Springer-Medizin-Verl; Bd. 31.2010, Suppl.2, S. 211-214
2009
Nicht begutachteter Zeitschriftenartikel
Krebspatienten brauchen ein individuelles psychologisches Angebot - 2. Magdeburger Psychoonkologisches Kolloquium
In: Ärzteblatt Sachsen-Anhalt . - Magdeburg : Ärztekammer Sachsen-Anhalt, Bd. 20.2009, 4, S. 50-54
Originalartikel in begutachteter internationaler Zeitschrift
A Novel Molecular Mechanism of Primary Resistance to FLT3-Kinase Inhibitors in Acute Myeloid Leukaemia.
In: Blood 2009 Apr 23;113(17):4063-73. Epub 2009 Jan 14.
Identification of a Novel Type of ITD Mutations Located in Non-Juxtamembrane Domains of the FLT3 Tyrosine Kinase Receptor.
In: Blood 2009 Apr 23;113(17):4074-7. Epub 2008 May 15.
Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma
In: British journal of haematology . - Oxford [u.a.] : Wiley-Blackwell, Bd. 147.2009, 1, S. 97-101
Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro
In: British journal of haematology . - Oxford [u.a.] : Wiley-Blackwell, Bd. 144.2009, 6, S. 865-874
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
In: Blood . - Washington, DC : American Society of Hematology, Bd. 114.2009, 12, S. 2386-2392
2008
Originalartikel in begutachteter internationaler Zeitschrift
Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment.
In: Blood 111(3):1039-43, 2008
The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukaemia.
In: Leuk Res. 2008 Nov;32(11):1698-708. Epub 2008 Jun 16.
Entwicklung von Tyrosinkinase-Inhibitoren bei hämatologischen Neoplasien. FLT3 und JAK2 als therapeutische Targets.
In: Pharm Unserer Zeit. 2008;37(5):394-403.
LS104, a non ATP-competitive small molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2-V617F positive cells.
In: Mol Cancer Ther 7(5): 1176-1184, 2008.
2007
Originalartikel in begutachteter internationaler Zeitschrift
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
In: Cancer 110:1509-19, 2007.
Co-expression of tyrosine kinase receptors in gastric adenocarcinoma ¿ a rationale for a new molecular targeting strategy?
In: World J Gastroenterol 13(26):3605-9, 2007.
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukaemia in myeloid blast crisis.
In: Cancer 109:1543-9, 2007.
A neoepitope generated by a FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T-cells.
In: Blood 109(7):2985-2988, 2007.
Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia.
In: Blood 109:4686-92, 2007
Results of a multicenter phase II trial for older patients with c-kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C (LDAC) and Imatinib (IM).
In: Cancer 109(5):907-14, 2007.
Cross-inhibition of IFN-induced signal transduction by GM-CSF through a block in STAT1- activation.
In: J Interferon Cytokine Res 27(11):947-59, 2007.
2006
Originalartikel in begutachteter internationaler Zeitschrift
Five-Year Follow-up of Imatinib Therapy for Newly Diagnosed Chronic Myeloid Leukemia in Chronic-Phase Shows Sustained Responses and High Overall Survival.
In: New England Journal of Medicine 355:2408-17, 2006
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
In: Clinical Cancer Research 1;12(15):4628-35, 2006.
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia (AML) by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
In: Blood 107(1):293-300, 2006.
Novel Bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinases.
In: Journal of Medicinal Chemistry 49: 3101-3115, 2006.
Histone deacetylase inhibition by valproic acid downregulates c-FLIP and sensitizes hepatoma cells towards CD95- and TRAIL-receptor mediated apoptosis and chemotherapy.
In: Oncology Reports 15: 227-230, 2006.
- Hämatologie/Onkologie
- Innere Medizin
- Onkogene Signaltransduktion
- bei gutartigen und bösartigen hämatologischen Erkrankungen;
- bei Leukämien, myelodysplastischem Syndrom, myeloproliferativen Neoplasien, Lymphomen, Multiplem Myelom (Plasmozytom);
- bei Tumorerkrankungen;
- bei Weichteilsarkomen;
- bei sogenanntem CUP -Syndrom.
Beratung zur hämatopoetischen Stammzelltransplantation
1980 - 1981 | Rumänisch Studium an der Universität Craiova, Rumänien |
1981 - 1982 | Medizinstudium an der Universität Cluj, Rumänien |
1982 - 1983 | Medizinstudium an der Georg-August-Universität Göttingen |
1983 - 1984 | Medizinstudium an der Medizinischen Hochschule Hannover |
1985 | Stipendiat der Soltenborn-Stiftung |
1984 - 1987 | Medizinstudium an der Georg-August-Universität Göttingen |
1987 - 1988 | Praktisches Jahr: Tufts University, Boston, USA (Stipendiat des "Biomedical Sciences Exchange Program between The United States and West Germany"); Krh. Seesen; Krh. Bad Harzburg |
AKADEMISCHE GRADE
1988 | Promotion zum Dr. med. an der Georg-August-Universität Göttingen, Bewertung: Magna cum laude |
2000 | Habilitation und venia legendi für das Fach "Innere Medizin" am Fachbereich Medizin der Johannes Gutenberg-Universität Mainz (Molekulare Untersuchungen zur Signaltransduktion IFN-induzierter Gene in leukämischen und normalen hämatopoetischen Zellen) |
BERUFLICHER WERDEGANG
10/1988 - 3/1990 | DFG-Postdoktorandenstipendium in der klinischen Arbeitsgruppe der Max-Planck-Gesellschaft an der Medizinischen Universitätsklinik Göttingen (Leiter: Prof. Dr. K. Pfizenmaier) |
4/1990 - 9/1990 | "Postdoctoral Research Fellowship am "Hospital for Sick Children , Toronto, Kanada (Prof. Dr. B. Williams) |
10/1990 - 11/1996 | Assistent an der III. Medizinischen Klinik der Johannes-Gutenberg-Universität Mainz (Direktor: Prof. Dr. C. Huber) |
1/1995 - 12/1995 | "Clinical Fellowship in Hämatologie/Onkologie am "Department for Hematology and Medical Oncology , Cleveland Clinic Foundation, Cleveland, USA |
5/1996 | Facharzt-Anerkennung Arzt für Innere Medizin |
12/1996 - 6/2008 | Oberarzt und Arbeitsgruppenleiter an der Medizinischen Klinik der Johannes Gutenberg-Universität Mainz. Aufbau und Leitung des wissenschaftlichen Labors für Onkogene Signaltransduktion. |
1/1998 | Anerkennung Hämatologie und Internistische Onkologie |
3/2001- 4/2004 | Medical Director und Vertreter von Prof. Dr. med. Christoph Huber an der III. Medizinischen Klinik und Poliklinik der Johannes Gutenberg-Universität Mainz. Strategisches, operatives, wirtschaftliches, personalführendes und administratives "Management" der III. Medizinischen Klinik und Poliklinik. |
3/2005 | Berufung auf eine Professur (W2) für "Leukämie- und Tumorforschung" im Fachbereich Medizin der Johannes Gutenberg-Universität Mainz an der III. Medizinischen Klinik und Poliklinik (Stiftungsprofessur). |
Seit 5/2009 | Univ.-Professor (W3) und Direktor der Klinik für Hämatologie und Onkologie an der Otto-von-Guericke-Universität Magdeburg |